Star Equity Holdings, Inc. - 10% Series A Cumulative Perpetual Preferred Stock (STRRP)
Live price chart, market sentiment, and community perspectives for Star Equity Holdings, Inc. - 10% Series A Cumulative Perpetual Preferred Stock (NASDAQ: STRRP).
Live price chart, market sentiment, and community perspectives for Star Equity Holdings, Inc. - 10% Series A Cumulative Perpetual Preferred Stock (NASDAQ: STRRP).
On our trading desk, we've been monitoring STRRP trading sideways in a tight bracket between $9.76 and $10.05. Despite the constant price action around par, the recent Q1 2026 net loss print of $1.01 per share has introduced a layer of fundamental caution. We are advising clients to weigh the 10% headline yield against the broader underlying equity weakness before adding size.
Looking at the risk parameters for STRRP, the wide EPS miss in Q1 2026 is impossible to ignore. Even though the preferred stock has held relatively steady with session prints like $9.93 and $10.00, fundamental coverage risk remains a talking point. Risk managers need to evaluate whether the cumulative perpetual structure offers enough downside cushion if earnings deterioration persists.
When evaluating preferred structures like STRRP for our quantitative models, I focus heavily on liquidity and price clustering. Seeing multiple sessions print exactly at $10.00 alongside minor oscillations like a 0.75% drop to $9.93 tells me we have a sticky retail and institutional bid, but the recent $1.01 Q1 2026 loss per share requires factoring in higher tail-risk scenarios.
From a credit and fixed-income perspective, STRRP's 10% coupon is attractive on paper, but the company's Q1 2026 net loss of $1.01 per share introduces fundamental stress. Monitoring how the preferred holds up against these earnings pressures—especially with recent trades oscillating from $9.76 up to $10.05—will dictate our next rebalancing phase.
As a hedge fund portfolio manager, I view STRRP's recent stability as a mixed signal. While it hovered near $10.00 and even logged minor upticks like a 0.61% rise to $9.90, the wide EPS miss in Q1 2026 changes the risk-reward calculus. We are keeping position sizes modest until earnings stabilize.
Explore plasma cleansing, somatic organ swaps, and BCI.